LQDA Trading Analysis - 10/23/2026 04:56 PM — TRU-SENTIMENT

News Headlines & Context:

The following recent news context is based on general knowledge of Liquidia Corporation (LQDA) and is separated from the data-driven analysis below.

• FDA approval of Yutrepia (treprostinil) for PAH and PH-ILD earlier in 2026 triggered a major re-rating, though a late-September sudden drop from ~$71 to $30 on a single day (seen in embedded data) suggests a catalyst such as a court ruling or partner dispute.
• October 14 spike to $33.84 on volume of 18.6M shares aligns with possible positive trial or commercial update for lead asset.
• No confirmed Q3 earnings date, but fiscal year end was Dec 2025 per fundamentals; upcoming catalyst risk remains elevated.
• General biotech sector momentum and options speculative flow likely tied to binary event anticipation rather than steady fundamentals.

Context: Headlines suggest binary catalysts explain the extreme volatility and volume clusters in the embedded price data, while options sentiment shows speculative bullish conviction despite weak technical structure.

Fundamental Analysis:

Based strictly on the provided FUNDAMENTALS data for LQDA:

• Trailing P/E: 23.20; Trailing EPS: $1.57 — valuation appears moderate vs typical biotech loss-makers, but PEG ratio, forward P/E, and revenue metrics are null (not provided).
• Market Cap: $3,817,558,850; Shares Outstanding: 89,509,000; Institutional Ownership: 43.01%.
• Dividend Yield: 0.00% (no income). Beta: 1.15 (moderate market correlation).
• 52-Week High: $93.61; 52-Week Low: $21.94 — current price $42.31 is mid-range but far off highs.
• Historical Volatility: 264.70% — extreme, reflecting binary event risk.
• Profit margins, ROE, Debt/Equity, Free Cash Flow, revenue growth, and analyst target price are all null/unavailable in data.
• Average Volume: 7,124,000 vs recent daily volume ~2.9M (Oct 23) — below average outside spike days.

Fundamentals show a profitable-looking EPS but lack depth; extreme HV and mid-cap size diverge from the broken technical trend (SMA50 $55.93 vs price $42.31).

Current Market Position:

Current price per indicators: $42.31 (close Oct 23 $42.30). From daily history, Oct 23 closed at $42.30 after trading range $38.69–$42.66. Minute bars show Oct 22 open $38.75 → Oct 23 15:55 close $42.61 with late-session volume surge (232,148 at 15:55). Intraday momentum positive, closing near high of two-day ramp from $38.65 to $42.83.

Technical Analysis:

SMA alignment: Price $42.31 > SMA5 $38.20 > SMA20 $35.73 but < SMA50 $55.93 — bullish short-term crossover, below long-term downtrend. RSI 84.90 indicates overbought. MACD negative (-5.70) with histogram -1.14 shows bearish momentum structure despite price rise (divergence). Bollinger: price above middle $35.73, room to upper $61.84. 30d range high $74.74, low $22.31 — price in upper third.

True Sentiment Analysis (Delta 40-60 Options):

Options flow via True Sentiment (Delta 40-60 only):

Call Volume: $1,395,620 (85.2%) Put Volume: $241,490 (14.8%) Total: $1,637,110

Sentiment: Bullish. Call contracts 2,062 vs put 183; conviction strongly directional long. Divergence: technicals show MACD bearish and SMA50 overhead, yet options scream bullish — matches spread engine note: "Divergence detected between technical indicators and options sentiment."

Key Price Levels (observational only):